Healthcare coverage and regulatory leadership moved simultaneously. A report says the White House withdrew FDA nominee Heidi Overton amid uncertainty over Senate support, leaving leadership momentum unclear for the regulator. In the payer-and-employer layer, Teladoc launched an employer-contribution option for GLP-1 medications, effectively redesigning cost-sharing to reduce patient out-of-pocket burden as demand for weight-loss and cardiometabolic drugs remains high.
Get the Daily Brief